128 related articles for article (PubMed ID: 37769226)
1. Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes.
Kasi PM; Bucheit LA; Liao J; Starr J; Barata P; Klempner SJ; Gandara D; Shergill A; Madeira da Silva L; Weipert C; Zhang N; Pretz C; Hardin A; Kiedrowski LA; Odegaard JI
JCO Precis Oncol; 2023 Sep; 7():e2300118. PubMed ID: 37769226
[TBL] [Abstract][Full Text] [Related]
2. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
Nakamura Y; Okamoto W; Denda T; Nishina T; Komatsu Y; Yuki S; Yasui H; Esaki T; Sunakawa Y; Ueno M; Shinozaki E; Matsuhashi N; Ohta T; Kato K; Ohtsubo K; Bando H; Hara H; Satoh T; Yamazaki K; Yamamoto Y; Okano N; Terazawa T; Kato T; Oki E; Tsuji A; Horita Y; Hamamoto Y; Kawazoe A; Nakajima H; Nomura S; Mitani R; Yuasa M; Akagi K; Yoshino T
JCO Precis Oncol; 2022 Feb; 6():e2100383. PubMed ID: 35188805
[TBL] [Abstract][Full Text] [Related]
3. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.
Stewart M; Norden AD; Dreyer N; Henk HJ; Abernethy AP; Chrischilles E; Kushi L; Mansfield AS; Khozin S; Sharon E; Arunajadai S; Carnahan R; Christian JB; Miksad RA; Sakoda LC; Torres AZ; Valice E; Allen J
JCO Clin Cancer Inform; 2019 Jul; 3():1-15. PubMed ID: 31335166
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
5. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.
Willis J; Lefterova MI; Artyomenko A; Kasi PM; Nakamura Y; Mody K; Catenacci DVT; Fakih M; Barbacioru C; Zhao J; Sikora M; Fairclough SR; Lee H; Kim KM; Kim ST; Kim J; Gavino D; Benavides M; Peled N; Nguyen T; Cusnir M; Eskander RN; Azzi G; Yoshino T; Banks KC; Raymond VM; Lanman RB; Chudova DI; Talasaz A; Kopetz S; Lee J; Odegaard JI
Clin Cancer Res; 2019 Dec; 25(23):7035-7045. PubMed ID: 31383735
[TBL] [Abstract][Full Text] [Related]
6. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
7. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer.
Chakrabarti S; Bucheit L; Starr JS; Innis-Shelton R; Shergill A; Dada H; Resta R; Wagner S; Fei N; Kasi PM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710297
[TBL] [Abstract][Full Text] [Related]
8. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
[TBL] [Abstract][Full Text] [Related]
9. Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Olsen S; Liao J; Hayashi H
Curr Oncol; 2022 Jul; 29(7):4811-4826. PubMed ID: 35877242
[TBL] [Abstract][Full Text] [Related]
10. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
van der Leest P; Hiddinga B; Miedema A; Aguirre Azpurua ML; Rifaela N; Ter Elst A; Timens W; Groen HJM; van Kempen LC; Hiltermann TJN; Schuuring E
Mol Oncol; 2021 Nov; 15(11):2910-2922. PubMed ID: 34449963
[TBL] [Abstract][Full Text] [Related]
12. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract][Full Text] [Related]
13. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
15. Detection of Microsatellite Instability from Circulating Tumor DNA by Targeted Deep Sequencing.
Cai Z; Wang Z; Liu C; Shi D; Li D; Zheng M; Han-Zhang H; Lizaso A; Xiang J; Lv J; Wu W; Zhang Z; Zhang Z; Yuan F; He S; Sun J
J Mol Diagn; 2020 Jul; 22(7):860-870. PubMed ID: 32428677
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
Latham A; Srinivasan P; Kemel Y; Shia J; Bandlamudi C; Mandelker D; Middha S; Hechtman J; Zehir A; Dubard-Gault M; Tran C; Stewart C; Sheehan M; Penson A; DeLair D; Yaeger R; Vijai J; Mukherjee S; Galle J; Dickson MA; Janjigian Y; O'Reilly EM; Segal N; Saltz LB; Reidy-Lagunes D; Varghese AM; Bajorin D; Carlo MI; Cadoo K; Walsh MF; Weiser M; Aguilar JG; Klimstra DS; Diaz LA; Baselga J; Zhang L; Ladanyi M; Hyman DM; Solit DB; Robson ME; Taylor BS; Offit K; Berger MF; Stadler ZK
J Clin Oncol; 2019 Feb; 37(4):286-295. PubMed ID: 30376427
[TBL] [Abstract][Full Text] [Related]
17. Serial Circulating Tumor DNA in Monitoring the Effect of Neoadjuvant and Adjuvant Immunotherapy in Patients With Colon Cancer: Case Series and Review of the Literature.
Qin Q; Yang K; Ma T; Wang H; Yu P; Yuan M; Chen Y; Wang H
J Immunother; 2022 Oct; 45(8):358-362. PubMed ID: 35980372
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
[TBL] [Abstract][Full Text] [Related]
19. Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing.
Al Zoughbi W; Fox J; Beg S; Papp E; Hissong E; Ohara K; Keefer L; Sigouros M; Kane T; Bockelman D; Nichol D; Patchell E; Bareja R; Karandikar A; Alnajar H; Cerqueira G; Guthrie VB; Verner E; Manohar J; Greco N; Wilkes D; Tagawa S; Malbari MS; Holcomb K; Eng KW; Shah M; Altorki NK; Sboner A; Nanus D; Faltas B; Sternberg CN; Simmons J; Houvras Y; Molina AM; Angiuoli S; Elemento O; Mosquera JM
Oncologist; 2021 Nov; 26(11):e1971-e1981. PubMed ID: 34286887
[TBL] [Abstract][Full Text] [Related]
20. Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
Li Y; Xu Z; Wang S; Zhu Y; Ma D; Mu Y; Ying J; Li J; Xing P
Thorac Cancer; 2022 Aug; 13(15):2201-2209. PubMed ID: 35778830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
